Cargando…
Interferon-β–Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring
A 48-year-old woman who had been receiving long-term interferon-β for 8 years for multiple sclerosis developed drug-induced World Health Organization group I pulmonary arterial hypertension. Triple therapy for pulmonary arterial hypertension and suspension of interferon-β led to improvement from a h...
Autores principales: | Raza, Farhan, Kozitza, Callyn, Chybowski, Amy, Goss, Kara N., Berei, Theodore, Runo, James, Eldridge, Marlowe, Chesler, Naomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311374/ https://www.ncbi.nlm.nih.gov/pubmed/34317680 http://dx.doi.org/10.1016/j.jaccas.2021.02.005 |
Ejemplares similares
-
Distinguishing exercise intolerance in early‐stage pulmonary hypertension with invasive exercise hemodynamics: Rest V
(E)/VCO(2) and ETCO(2) identify pulmonary vascular disease
por: Raza, Farhan, et al.
Publicado: (2022) -
Multimodality Deep Phenotyping Methods to Assess Mechanisms of Poor Right Ventricular–Pulmonary Artery Coupling
por: Raza, Farhan, et al.
Publicado: (2022) -
Pulmonary vascular distensibility with passive leg raise is comparable to exercise and predictive of clinical outcomes in pulmonary hypertension
por: Kozitza, Callyn J., et al.
Publicado: (2022) -
Prevalence of aortic stenosis and TAVR outcomes in patients with systemic sclerosis‐associated pulmonary hypertension
por: Alman, Kirsten, et al.
Publicado: (2022) -
Development of a PET/MRI exercise stress test for determining cardiac glucose dependence in pulmonary arterial hypertension
por: Barton, Gregory P., et al.
Publicado: (2022)